Bone Biologics Corporation (BBLG)

Market Cap	1.04M -73.4%
Revenue (ttm)	n/a
Net Income	-2.89M
EPS	-1.61
Shares Out	2.76M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,824
Open	0.3900
Previous Close	0.3948
Day's Range	0.3700 - 0.4074
52-Week Range	0.3700 - 2.3900
Beta	0.57
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 26, 2026

About BBLG

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or b...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 2
• Stock Exchange: Nasdaq
• Ticker Symbol: BBLG
• Website: https://www.bonebiologics.com

Financial Performance

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 27, 2026

Data Sources Report a data error